This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as nimotuzumab and nivolumab, may block tumor growth in different ways by targeting certain cells.
A Phase I/II Open-label Study of Nimotuzumab in Combination with Nivolumab
in Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck
To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail email@example.com.